Low-dose aspirin discontinuation and risk of cardiovascular events: A swedish nationwide, population-based cohort study

Circulation

Volumn 136, Issue 13, 2017, Pages 1183-1192

  Sundström, Johan ^a   Hedberg, Jakob ^a   Thuresson, Marcus ^b   Aarskog, Pernilla ^c   Johannesen, Kasper Munk ^d   Oldgren, Jonas ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b STATISTICON AB   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Aspirin; Cohort studies; Primary prevention; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; CARDIOVASCULAR DISEASES; INCIDENCE; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; SWEDEN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; SWEDEN;

EID: 85030791940     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.028321     Document Type: Article

References (25)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372. doi: 10.1161/CIRCULATIONAHA.106.174516.
3. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28:2375-2414. doi: 10.1093/eurheartj/ehm316.
4. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK. Effect of aspirin on vascular and nonvascular outcomes: metaanalysis of randomized controlled trials. Arch Intern Med. 2012;172:209-216 doi: 10.1001/archinternmed.2011.628.
5. Antithrombotic Trialists' Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
6. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N. Lowdose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510-2520. doi: 10.1001/ jama.2014.15690.
7. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, Granger CB, Erickson S, White K, Steg PG. Adherence to evidencebased therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117:73-81. doi: 10.1016/j.amjmed.2003.12.041.
8. Sud A, Kline-Rogers EM, Eagle KA, Fang J, Armstrong DF, Rangarajan K, Otten RF, Stafkey-Mailey DR, Taylor SD, Erickson SR. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother. 2005;39:1792-1797. doi: 10.1345/aph.1G249.
9. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J. 2006;151:185-191.
10. Mostaza JM, Lahoz C, Martín-Jadraque R, Sanmartín MA, Vicente I, Tranche S, Taboada M, Mantilla T, Monteiro B, Sanchez-Zamorano MA; PRESENAP Study. Factors associated with the discontinuation of evidence- based cardiovascular therapies in patients with stable coronary artery disease: a primary care perspective. Eur J Cardiovasc Prev Rehabil. 2009;16:34-38. doi: 10.1097/HJR.0b013e32831a47f3.
11. Herlitz J, Tóth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10:125-141. doi: 10.2165/11318440-000000000-00000.
12. Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ. 2011;343:d4094.
13. García Rodríguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011;76:740-746. doi: 10.1212/ WNL.0b013e31820d62b5.
14. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62:1217-1220. doi: 10.1001/archneur.62.8.1217.
15. Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005;257:399-414. doi: 10.1111/j.1365- 2796.2005.01477.x.
16. Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, Beygui F, Payot L, Vignolles N, Metzger JP, Thomas D. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361-2367. doi: 10.1161/01. CIR.0000145171.89690.B4.
17. Oscarsson A, Gupta A, Fredrikson M, Järhult J, Nyström M, Pettersson E, Darvish B, Krook H, Swahn E, Eintrei C. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010;104:305-312. doi: 10.1093/bja/aeq003.
18. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, Chan FK. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1-9. doi: 10.7326/0003-4819-152-1-201001050-00179.
19. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R, Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S; POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370:1494-1503. doi: 10.1056/ NEJMoa1401105.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497. doi: 10.1056/NEJMra050100.
21. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi: 10.1186/1471-2458-11-450.
22. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. BMC Med Res Methodol. 2008;8:70. doi: 10.1186/1471-2288-8-70.
23. McDonald JW, Ali M. Recovery of cyclooxygenase activity after aspirin in populations of platelets separated on stractan density gradients. Prostaglandins Leukot Med. 1983;12:245-252.
24. Vial JH, McLeod LJ, Roberts MS. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:157-160.
25. Doutremepuich C, Aguejouf O, Desplat V, Eizayaga FX. Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals. Cardiovasc Hematol Disord Drug Targets. 2010;10:103-110.